VivoSeq
Other

Hemiplegia

5

Pipeline Programs

2

Active Trials

4

Companies Involved

Hemiplegia is an early-stage landscape with 5 programs across 4 companies. The most active players are Jazz Pharmaceuticals, Vitae Pharmaceuticals Inc., an Allergan affiliate, Ultragenyx. 1 therapy is approved with 1 more in late-stage development.

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

15/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Trial Status

6

clinical trials

Completed3 · 50%
Active, not recruiting2 · 33%
Unknown status1 · 17%

Trial Activity

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)